The estimate, shared by M Mohan, starts from about $141 billion in 2025, with North America holding roughly 62% and semaglutide and tirzepatide leading.
Recap by typeshit. Post by M Mohan on X.
Canada is one of the first big markets where semaglutide goes off patent. IQVIA plans ongoing updates on pricing, coverage and generic uptake.
The Medicare GLP-1 Bridge pilot runs July 2026 through 2027, covering FDA-approved pills and shots with no deductible for eligible Part D enrollees.
The two drugs brought in $14.9 billion of Lilly's $23.0 billion fiscal Q2 revenue while US prices fell 9%, Trefis says. The Q3 report is expected around October 29.
Novo Nordisk is lowering what Wegovy costs in China, a fresh move in the race for the country's obesity drug market. No figures were given.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
Drugs.com
Eligibility usually starts at a BMI of 30, or 27 with a weight-related condition. The piece also covers costs, side effects and why most people stay on these drugs long term.
Loading…